Cardiovascular disease (CVD) continues to be a leading cause of morbidity and mortality in American men and women and in all of the Western world, despite declines in annual death rates attributed to CVD in the US. CVD accounts for 1 of every 2.8 deaths in the United States. Additionally, CVD has become the number-one cause of death in the developing world. Due to the increase in prevalence of risk factors combined with a relative lack of access to preventative interventions, a younger population is afflicted by CVD in the developing world with enormous social and economic implications.
In the US, the economic impact on the health care system increases as the population ages. In 2008, the estimated cost of health care expenditures and lost productivity attributable to cardiovascular diseases was $448.5 billion. $156.4 billion of it is attributable to Ischemic Heart Disease (IHD) cost alone. In the developing world, the economic impact comes in both direct costs to the health care system and the indirect costs of withdrawal from the work force during prime years of productivity.
The HyperQ™ System revolutionizes the field of non-invasive coronary artery disease diagnosis.
- The HyperQ™ System is a dual mode, top of the line device combining all the functionalities of standard stress ECG systems with the unique HyperQ analysis. Importantly, the test performed using the HyperQ system utilizes standard ECG stress protocols providing the physician with a familiar procedure of standard duration. The only difference is that the HyperQ system provides enhanced ECG analysis in addition to all standard ECG parameters.
- HyperQ™ refers to acquisition of the ECG signal at high frequencies. Traditional ECG is read at low frequencies. BSP harnesses the valuable information found in the higher frequencies to extract more accurate results from the ECG tracing.
- HyperQ™ prevents unnecessary exposure to radioactive or invasive procedures in patients that are inherent in other advanced IHD diagnosis systems. By using the HyperQ System you can attain levels of sensitivity and specificity similar to those of radioactive procedures.
- Accuracy equivalent in men and women. While Stress test accuracy in women is notoriously low, the HyperQ diagnosis performs equally well in men and women, thus allowing for a dramatically enhanced diagnosis in women.
- Using the HyperQ™ System significantly reduces health care system costs. Accurate diagnosis by the HyperQ™ saves the time and cost of other further, expensive IHD tests.
- Clinical trial results have been presented at conferences in Europe and the US and published in leading cardiology journals. To date, thousands of patients have been examined by the HyperQ™ System in controlled clinical studies, hospitals and private physician offices.
The HyperQ™ System received US FDA clearance (510K), as well as the European CE marking.
|“…opening the door to the long sought screening test for ischemic heart disease.” (More…)Prof. Boris Strasberg, MD
Deputy Director, Cardiology Department, Rabin Medical Center
|“I believe that the HyperQ system significantly improves the sensitivity and specificity for detecting myocardial ischemia.” (More…)Itzhak Herz, MD
Senior attending cardiologist, Catheterization laboratory, Ichilov Hospital
|“…I believe that the HyperQ system revolutionizes the field of non invasive, inexpensive diagnosis of ischemic heart disease.” (More…)Haim Silber, MD
Maccabi Healthcare Services
|” I am convinced that the HyperQ system offers an important advance in the diagnosis of ischemic heart disease.” (More…)Prof. Ori Ben-Yehuda, MD
Director, Coronary Care Unit, University of California, San Diego
|” Efficient and accurate assessment for ischemia with the HyperQ system may improve upon other noninvasive diagnostic tests, reduce costs to the healthcare system…” (More…)Jared M. Widell, MD Director, Stress Echo Lab Washington Hospital Center||“…Our experience with the HyperQ System has been excellent… the system may reduce the number of unnecessary angiography procedures in women. .” (More…)David Rosenman, MD
Head of the Non-Invasive Cardiology Unit, Shaare Zedek Medical Center